testosterone undecanoate · Verity · NDA 208088

Tlando

Earliest generic entry, as listed
28 Apr 2041

Blocked by patent: US 11464735, US 12691057.

Listed patents · 15 unexpired

16 Orange Book listing rows for 15 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 11464735drug product, use U-1500 · sets the listed date28 Apr 2041
US 12691057drug product, use U-4194 · sets the listed date28 Apr 2041
US 12011503drug product, use U-3964, U-396516 Oct 2040
US 12011503 listing rowdrug product, use U-396416 Oct 2040
US 12011503 listing rowdrug product, use U-396516 Oct 2040
US 12310978use U-419421 Feb 2039
US 11559530use U-150028 Nov 2037
US 10226473use U-150030 Nov 2030
US 10716794use U-150030 Nov 2030
US 11311555use U-150030 Nov 2030
US 11364249use U-150030 Nov 2030
US 11433083use U-150030 Nov 2030
US 9943527use U-150030 Nov 2030
US 9949985use U-150030 Nov 2030
US 11304960drug product, use U-15008 Jan 2029
US 8778922drug product, use U-15008 Jan 2029
US 8865695use U-15008 Jan 2029

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
208088 · 001 · RLDcapsule, oral112.5MG28 Apr 2041